Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Myelodysplastic Syndrome
Related studies linked through entity extraction aliases.
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE3
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
- Status
- TERMINATED
- Phase
- PHASE2
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
- Status
- COMPLETED
- Phase
- NA
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
- Status
- TERMINATED
- Phase
- PHASE2
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Status
- RECRUITING
- Phase
- PHASE1
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome
- Status
- UNKNOWN
- Phase
- PHASE2
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
- Status
- TERMINATED
- Phase
- PHASE2
Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study
- Status
- WITHDRAWN
- Phase
- NA
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
- Status
- WITHDRAWN
- Phase
- PHASE3
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
- Status
- COMPLETED
- Phase
- PHASE2
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1